Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$11.4 million.

  • Avalo Therapeutics' Non Operating Income fell 13181.36% to -$11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.2 million, marking a year-over-year decrease of 16054.4%. This contributed to the annual value of $33.5 million for FY2024, which is 90155.54% up from last year.
  • Per Avalo Therapeutics' latest filing, its Non Operating Income stood at -$11.4 million for Q3 2025, which was down 13181.36% from -$1.4 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Non Operating Income registered a high of $108.0 million during Q2 2024, and its lowest value of -$88.5 million during Q1 2024.
  • Over the past 5 years, Avalo Therapeutics' median Non Operating Income value was -$1.0 million (recorded in 2023), while the average stood at $599842.1.
  • As far as peak fluctuations go, Avalo Therapeutics' Non Operating Income crashed by 1086363.64% in 2021, and later skyrocketed by 1052905.41% in 2024.
  • Over the past 5 years, Avalo Therapeutics' Non Operating Income (Quarter) stood at -$1.2 million in 2021, then rose by 19.85% to -$949000.0 in 2022, then soared by 45.31% to -$519000.0 in 2023, then plummeted by 4122.35% to -$21.9 million in 2024, then skyrocketed by 47.91% to -$11.4 million in 2025.
  • Its Non Operating Income was -$11.4 million in Q3 2025, compared to -$1.4 million in Q2 2025 and $1.5 million in Q1 2025.